Diagnostic strategies to investigate cerebrospinal fluid involvement in haematological malignancies

Leukemia Research

Volumn 37, Issue 3, 2013, Pages 231-237

  Galati, Domenico ^a   Di Noto, Rosa ^b,c   Del Vecchio, Luigi ^b,c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cerebrospinal fluid; CSF; Haematological malignancies; Leptomeninges; Meningeal involvement; Neoplastic meningitis

Indexed keywords

BETA 2 MICROGLOBULIN; CD27 ANTIGEN; DNA; FIBRONECTIN; INTERLEUKIN 2; LACTATE DEHYDROGENASE;

ALGORITHM; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA TEMPLATE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEASIBILITY STUDY; FLOW CYTOMETRY; GOLD STANDARD; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; MENINX DISORDER; MOLECULAR DIAGNOSIS; MOLECULAR GENETICS; NEUROIMAGING; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CEREBROSPINAL FLUID; DIAGNOSTIC TECHNIQUES AND PROCEDURES; HEMATOLOGIC NEOPLASMS; HUMANS; MEDICAL ONCOLOGY; MOLECULAR DIAGNOSTIC TECHNIQUES; TUMOR MARKERS, BIOLOGICAL;

EID: 84872975891     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.11.016     Document Type: Review

References (73)

1. Posner J.B. Leptomeningeal metastases. Neurologic complications of cancer 1995, Oxford University Press, New York, p.143. 1st ed.
2. Chamberlain M.C. Neoplastic meningitis. Neurologist 2006, 12:179-187.
3. Haioun C., Besson C., Lepage E., Thieblemont C., Simon D., Rose C., et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Ann Oncol 2000, 11:685-690.
4. Hollender A., Kvaloy S., Nome O., Skovlund E., Lote K., Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002, 13:1099-1107.
5. Kantarjian H.M., Walters R.S., Smith T.L., Keating M.J., Barlogie B., McCredie K.B., et al. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 1988, 72:1784-1789.
6. Fassas A.B.T., Muwalla F., Berryman T., Benramdane R., Joseph L., Anaissie E., et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol 2002, 117:103-108.
7. Jabbour E., Thomas D., Cortes J., Kantarjian H.M., O'Brien S. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia. Cancer 2010, 116:2290-2300.
8. Pui C.H., Thiel E. Central nervous system disease in hematological malignancies: historical perspective and practical applications. Semin Oncol 2009, 36:S2-S16.
9. Ferreri A.J.M., Assanelli A., Crocchiolo R., Ciceri F. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. Hematol Oncol 2009, 27:61-70.
10. Kaplan J.G., DeSouza T.G., Farkash A., Shafran B., Pack J., Rehman F. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990, 9:225-229.
11. Chamberlain M.C., Sandy A., Press G.A. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990, 40:435-438.
12. Zeiser R., Burger J.A., Bley T.A., Windfuhr-Blum M., Schulte-Mönting J., Behringer D.M. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis - a single centre experience. Br J Haematol 2004, 124:762-768.
13. Freilich R.J., Krol G., De Angelis L.M. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastases. Ann Neurol 1995, 38:51-57.
14. Pauls S., Fischer A.C., Brambs H.J., Fetscher S., Höche W., Bommer M. Use of magnetic resonance imaging to detect neoplastic meningitis: limited use in leukemia and lymphoma but convincing results in solid tumors. Eur J Radiol 2012, 81(5):974-978.
15. De Angelis L.M., Cairncross J.G. A better way to find tumor in the CSF?. Neurology 2002, 58:339-340.
16. Schiff D., Feske S.K., Wen P.Y. Deceptively normal ventricular fluid in lymphomatous meningitis. Arch Intern Med 1993, 153:389-390.
17. Glass J.P., Melamed M., Chernik N.L., Posner J.B. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979, 29:1369-1375.
18. Glantz M.J., Cole B.F., Glantz L.K., Cobb J., Mills P., Lekos A., et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998, 82:733-739.
19. Chamberlain M.C., Kormanik P.A., Glantz M.J. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neurooncol 2001, 3:42-45.
20. Hooijkaas H., Hählen K., Adriaansen H.J., Dekker I., van Zanen G.E., van Dongen J.J. Terminal deoxynucleotidyl transferase (TdT)-positive cells in cerebrospinal fluid and development of overt CNS leukemia: a 5-year follow-up study in 113 children with a TdT-positive leukemia or non-Hodgkin's lymphoma. Blood 1989, 74:416-422.
21. Desai K., Fallon M.A., Willard-Smith D., Wilbur D.C. Improving the diagnostic accuracy of cytologic cerebrospinal fluid examinations in acute lymphoblastic leukemia using high-power microscopy and terminal deoxynucleotidyl transferase determinations. Diagn Cytopathol 1997, 16(May):413-419.
22. Perske C., Nagel I., Nagel H., Strik H. CSF cytology-the ongoing dilemma to distinguish neoplastic and inflammatory lymphocytes. Diagn Cytopathol 2011, 39:621-626.
23. Ward M.S. The use of flow cytometry in the diagnosis and monitoring of malignant hematological disorders. Pathology 1999, 31:382-392.
24. French C.A., Dorfman D.M., Shaheen G., Cibas E.S. Diagnosing lymphoproliferative disorders involving the cerebrospinal fluid: increased sensitivity using flow cytometric analysis. Diagn Cytopathol 2000, 23:369-374.
25. Finn W.G., Peterson L.C., James C., Goolsby C.L. Enhanced detection of malignant lymphoma in cerebrospinal fluid by multiparameter flow cytometry. Am J Clin Pathol 1998, 110:341-346.
26. Moriarty A.T., Wiersema L., Snyder W., Kotylo P.K., McCloskey D.W. Immunophenotyping of cytologic specimens by flow cytometry. Diagn Cytopathol 1993, 9:252-258.
27. Craig F.E., Ohori N.P., Gorrill T.S., Swerdlow S.H. Flow cytometric immunophenotyping of cerebrospinal fluid specimens. Am J Clin Pathol 2011, 135(1):22-34.
28. Subirà D., Castanon S., Romàn A., Aceituno E., Jimenez-Garofano C., Jimenez A., et al. Flow cytometry and the study of central nervous disease in patients with acute leukaemia. Br J Haematol 2001, 112:381-384.
29. Svenningsson A., Andersen O., Edsbagge M., Stemme S. Lymphocyte phenotype, subset distribution in normal cerebrospinal fluid. J Neuroimmunol 1995, 63:39-46.
30. Vrethem M., Dahle C., Ekerfelt C., Forsberg P., Danielsson O., Ernerudh J. CD4 and CD8 lymphocyte subsets in cerebrospinal fluid and peripheral blood from patients with multiple sclerosis, meningitis and normal controls. Acta Neurol Scand 1998, 97:215-220.
31. Subirà D., Castanon S., Aceituno E., Jimenez-Garofano C., Jimenez A., Jimenez A.M., et al. Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice. Am J Clin Pathol 2002, 117:952-958.
32. Kraan J., Gratama J.W., Haioun C., Orfao A., Plonquet A., Porwit A., et al. Flow cytometric immunophenotyping of cerebrospinal fluid. Curr Protoc Cytom 2008, 1-6. (6.25).
33. Stacchini A., Aliberti S., Demurtas A., Benevolo G., Godio L. Ten antibodies, six colors, twelve parameters: a multiparameter flow cytometric approach to evaluate leptomeningeal disease in B-cell non-Hodgkin's lymphomas. Cytometry B Clin Cytom 2012, 82(3):139-144.
34. Tembhare P., Yuan C.M., Morris J.C., Janik J.E., Filie A.C., Stetler-Stevenson M. Flow cytometric immunophenotypic assessment of T-cell clonality by vβ repertoire analysis in fine-needle aspirates and cerebrospinal fluid. Am J Clin Pathol 2012, 137(2):220-226.
35. Ahluwalia M.S., Wallace P.K., Peereboom D.M. Flow cytometry as a diagnostic tool in lymphomatous or leukemic meningitis: ready for prime time?. Cancer 2012, 118(7):1747-1753.
36. Schinstine M., Filie A.C., Wilson W., Stetler-Stevenson M., Abati A. Detection of malignant hematopoietic cells in cerebral spinal fluid previously diagnosed as atypical or suspicious. Cancer (Cancer Cytopathol) 2006, 108(3):157-162.
37. Nuckel H., Novotny J.R., Noppeney R., Savidou I., Duhrsen S. Detection of malignant haematopoietic cells in the cerebrospinal fluid by conventional cytology and flow cytometry. Clin Lab Haematol 2006, 28:22-29.
38. Hegde U., Filie A., Little R.F., Janik J.E., Grant N., Steinberg S.M., et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005, 105:496-502.
39. Di Noto R., Scalia G., Abate G., Gorrese M., Pascariello C., Raia M., et al. Critical role of multidimensional flow cytometry in detecting occult leptomeningeal disease in newly diagnosed aggressive B-cell lymphomas. Leukemia Res 2008, 32:1196-1199.
40. Quijano S., Lopez A., Sancho J.M., Panizo C., Guillermo D., Castilla C., et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol 2009, 27:1462-1469.
41. Bromberg J.E.C., Breems D.A., Kraan J., Bikker G., van der Holt B., Sillevis Smitt P., et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology 2007, 68:1674-1679.
42. Alvarez R., Dupuis J., Plonquet A., Christov C., Copie-Bergman C., Hemery F., et al. Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma. Ann Oncol 2012, 23(5):1274-1279.
43. Batchelor T., Loeffler J.S. Primary CNS lymphoma. J Clin Oncol 2006, 24(8):1281-1288.
44. Abrey L.E., Batchelor T.T., Ferreri A.J., Gospodarowicz M., Pulczynski E.J., Zucca E., et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005, 23(22):5034-5043.
45. Schroers R., Baraniskin A., Heute C., Vorgerd M., Brunn A., Kuhnhenn J., et al. Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. Eur J Haematol 2010, 85:520-528.
46. Broussalis E., Hutterer M., Oppermann K., Wipfler P., Pilz G., Harrer A., et al. Isolated leptomeningeal infiltration of a primary CNS B-cell lymphoma diagnosed by flow cytometry and confirmed by necropsy. Acta Neurol Scand 2011 Dec, 26. [epub ahead of print].
47. Urrego P.A., Smethurst M., Fowkes M., Peterson B., Strauchen J., Wu M., et al. plasmablastic lymphoma: report of a case with CSF cytology, flow cytometry, radiology, histological correlation, and review of the literature. Diagn Cytopathol 2011, 39(8):616-620.
48. Benevolo G., Stacchini A., Spina M., Ferreri A.J., Arras M., Bellio L., et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood 2012, 120(16):3222-3228.
49. Galoin S., Daste G., Apoil P.A., Chollet F., Roda D., Blancher A., et al. Polymerase chain reaction on cerebrospinal fluid cells in the detection of leptomeningeal involvement by B-cell lymphoma and leukaemia: a novel strategy and its implications. Br J Haematol 1997, 99(1):122-130.
50. Storch-Hagenlocher B., Haas J., Vogt-Schaden M.E., Bentz M., Hoffmann L.A., Biessmann A., et al. Molecular analysis of the CDR3 encoding region of the immunoglobulin heavy chain locus in cerebrospinal fluid cells as a diagnostic tool in lymphomatous meningitis. Ann Neurol 2000, 47:211-217.
51. Scrideli C.A., Queiroz R.P., Takayanagui O.M., Bernardes J.E., Tone L.G. Polymerase chain reaction on cerebrospinal fluid cells in suspected leptomeningeal involvement in childhood acute lymphoblastic leukemia: comparison to cytomorphological analysis. Diagn Mol Pathol 2003, 12(3):124-127.
52. Sayed D., Badrawy H., Ali A.M., Shaker S. Immunophenotyping and immunoglobulin heavy chain gene rearrangement analysis in cerebrospinal fluid of pediatric patients with acute lymphoblastic leukemia. Leukemia Res 2009, 33:655-661.
53. de Haas V., Vet R.J.W.M., Verhagen O.J.H.M., Kroes W., van den Berg H., van der Schoot C.E. Early detection of central nervous system relapse by polymerase chain reaction in children with B-precursor acute lymphoblastic leukemia. Ann Hematol 2002, 81:59-61.
54. Ekstein D., Ben-Yehuda D., Slyusarevsky E., Lossos A., Linetsky E., Siegal T. CSF analysis of IgH gene rearrangement in CNS lymphoma: relationship to the disease course. J Neurol Sci 2006, 247:39-46.
55. D'Alessio F., Mirabelli P., Mariotti E., Raia M., Di Noto R., Fortunato G., et al. Miniaturized flow cytometry-based BCR-ABL immunoassay in detecting leptomeningeal disease. Leukemia Res 2011, 35:1290-1293.
56. Stacchini A. Flow cytometric detection of BCR-ABL in cerebrospinal fluid. Leukemia Res 2011, 35(10):1286-1287.
57. Chamberlain M.C. Neoplastic, meningitis. The Neurologist 2006, 12(4):179-187.
58. Ernerudh J., Olsson T., Berlin G., Gustafsson B., Karlsson H. Cell surface markers for diagnosis of central nervous system involvement in lymphoproliferative disease. Ann Neurol 1986, 20:610-615.
59. Mavligit G.M., Stuckey S.E., Cabanillas F.F., Keating M.J., Tourtellotte W.W., Schold S.C., et al. Diagnosis of leukemia or lymphoma in the central nervous system by β2-microglobulin determination. N Engl J Med 1980, 303:718-722.
60. Rajantie J., Koskiniemia M., Siimes M.A., Salonen E., Vahere A.I. CSF fibronectin in Burkitt's lymphoma: an early marker for CNS involvement. Eur J Haematol 1989, 42:313-314.
61. Weller M., Stevens A., Sommer N., Melms A., Dichgans J., Wiethölter H. Comparative analysis of cytokine patterns in immunological, infectious and oncological neurological disorders. J Neurol Sci 1991, 104:215-221.
62. Ernerudh J., Olsson T., Berlin G., von Schenk H. Cerebrospinal fluid immunoglobulins and β2-microglobulin in lymphoproliferative and other neoplastic disease of the central nervous system. Arch Neurol 1987, 44:915-920.
63. Weller M., Stevens A., Sommer N., Schabet M., Wiethölter H., Humoral CSF parameters in the differential diagnosis of hematologic CNS neoplasia. Acta Neurol Scand 1992, 86:129-133.
64. Lee W., Kim S.J., Lee S., Kim J., Kim M., Lim J., et al. Significance of cerebrospinal fluid sIL-2R level as a marker of CNS involvement in acute lymphoblastic leukemia. Ann Clin Lab Sci 2005, 35(4):407-412.
65. Kersten M.J., Evers L.M., Dellemijn P., Portegies P., Hintzen R.Q., van Lier R., et al. Elevation of cerebrospinal fluid soluble CD-27 levels in patients with meningeal localization of lymphoid malignancies. Blood 1996, 87:1985-1989.
66. van den Bent M.J., Lamers C.H.J., vant Veer M.B., Sillevis Smitt P.A.E., Bolhuis R.L.H., Gratama J.W. Increased levels of soluble CD27 in the cerebrospinal fluid are not diagnostic for leptomeningeal involvement by lymphoid malignancies. Ann Hematol 2002, 81:187-191.
67. Brunn A., Montesinos-Rongen M., Strack A., Reifenberger G., Mawrin C., Schaller C., et al. Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma. Acta Neuropathol (Berl) 2007, 114:271-276.
68. Jahnke K., Coupland S.E., Na I.K., Loddenkemper C., Keilholz U., Korfel A., et al. Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma. Blood 2005, 106:384-385.
69. Smith J.R., Braziel R.M., Paoletti S., Lipp M., Uguccioni M., Rosenbaum J.T. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 2003, 101:815-821.
70. Smith J.R., Falkenhagen K.M., Coupland S.E., Chipps T.J., Rosenbaum J.T., Braziel R.M., et al. cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1. Am J Clin Pathol 2007, 127:633-641.
71. Fischer L., Korfel A., Pfeiffer S., Kiewe P., Volk H.D., Cakiroglu H., et al. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res 2009, 15:5968-5973.
72. Roy S., Josephson S.A., Fridlyand J., Cigall Kadoch J.K., Karrim J., Damon L., et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol 2008, 26:96-105.
73. Chamberlain M. Neoplastic meningitis. The Lancet 2006, 5:443-452.